Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTI-2040 + docetaxel
- Development stage
- Unknown
- Lead developer
- Aptose Biosciences
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
GTI-2040 + docetaxel is an investigational combination therapy for cancer. GTI-2040 is a 20-mer antisense oligonucleotide that specifically targets the mRNA of the R2 small subunit of human ribonucleotide reductase, an enzyme essential for DNA synthesis and cell proliferation. By binding to this mRNA, GTI-2040 decreases both mRNA and protein levels of R2, thereby inhibiting tumor cell proliferation[1][6][10]. Docetaxel is a well-established chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination aims to enhance antitumor efficacy by simultaneously disrupting DNA synthesis (via ribonucleotide reductase inhibition) and mitosis (via microtubule stabilization). This regimen has been explored in clinical trials for various solid tumors.
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on GTI-2040 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTI-2040 + docetaxel.